NYSE · HIMS

Hims & Hers Health, Inc.

$30.24 +$2.15 (+7.65%) 1D Pre-market

Key Metrics

$6.50B
Market cap
P/E · TTM
$2.37B
Revenue · TTM
−$13.24M
Net income
EPS · TTM $-0.05
Dividend yield
Free cash flow $60.37M
Beta · 1Y 2.40
EBITDA · TTM $30.06M
Gross margin 71.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 17
    A material event was filed (Form 8-K).

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 9
    The stock moved +40.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 9
  • Feb 27
    From its Jan 29 high, the share price fell 51%.

    Peak close $29.87 on Jan 29; trough close $14.52 on Feb 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -51%
  • Feb 9
    The stock moved -16.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 9

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$6.50B
Enterprise value
Shares outstanding231.5M
52-wk range$13.74 – $70.43
Avg volume · 20D11.4M
Net cash
Book value / share$1.81
IndustryServices-Offices & Clinics Of Doctors Of Medicine
ExchangeNYSE
About Hims & Hers Health, Inc.
IPO dateJan 21, 2021
Employees2442

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S2.74
P/FCF107.69
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 71.7%
Operating -1.6%
Net -0.6%
FCF 2.5%
ROE / ROIC -2.9% · 4.3%

Financial Health

Current ratio1.69
Quick ratio1.56
Debt / equity
Debt / EBITDA
Net cash
Working capital$426.59M

Cash Flow · TTM

Operating CF $280.27M
Capex −$219.90M
Free cash flow $60.37M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

3.2
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings